Basilea

Ad hoc announcement pursuant to Art. 53 LR (IN BRIEF) Basilea Pharmaceutica has been awarded USD 6 million by the Biomedical Advanced Research and Development Authority to continue development of its investigational oral antibiotic ceftibuten-ledaborbactam etzadroxil for treating complicated urinary … Read the full press release →

(IN BRIEF) Basilea Pharmaceutica has partnered with INCATE, the European incubator for antibacterial therapies, to support the advancement of early-stage anti-infective innovations. As an industry partner, Basilea brings deep expertise in antibacterial and antifungal drug development, while expanding INCATE’s scope … Read the full press release →

(IN BRIEF) Basilea Pharmaceutica has entered into a strategic collaboration with Prokaryotics to develop a first-in-class broad-spectrum antifungal therapy targeting severe invasive fungal infections. The partnership focuses on novel compounds with a new mode of action aimed at pathogens such … Read the full press release →